Research ExplorerPublicationsLocalized Ewing tumor of bone: final results of the cooperat...

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.

Standard

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. / Paulussen, M; Ahrens, S; Dunst, J; Winkelmann, W; Exner, G U; Kotz, R; Amann, G; Dockhorn-Dworniczak, B; Harms, D; Müller-Weihrich, S; Welte, K; Kornhuber, B; Janka-Schaub, Gritta; Göbel, U; Treuner, J; Voûte, P A; Zoubek, A; Gadner, H; Jürgens, H.

In: J CLIN ONCOL, Vol. 19, No. 6, 6, 2001, p. 1818-1829.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Paulussen, M, Ahrens, S, Dunst, J, Winkelmann, W, Exner, GU, Kotz, R, Amann, G, Dockhorn-Dworniczak, B, Harms, D, Müller-Weihrich, S, Welte, K, Kornhuber, B, Janka-Schaub, G, Göbel, U, Treuner, J, Voûte, PA, Zoubek, A, Gadner, H & Jürgens, H 2001, 'Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.', J CLIN ONCOL, vol. 19, no. 6, 6, pp. 1818-1829. <http://www.ncbi.nlm.nih.gov/pubmed/11251014?dopt=Citation>

APA

Paulussen, M., Ahrens, S., Dunst, J., Winkelmann, W., Exner, G. U., Kotz, R., Amann, G., Dockhorn-Dworniczak, B., Harms, D., Müller-Weihrich, S., Welte, K., Kornhuber, B., Janka-Schaub, G., Göbel, U., Treuner, J., Voûte, P. A., Zoubek, A., Gadner, H., & Jürgens, H. (2001). Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J CLIN ONCOL, 19(6), 1818-1829. [6]. http://www.ncbi.nlm.nih.gov/pubmed/11251014?dopt=Citation

Vancouver

Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J CLIN ONCOL. 2001;19(6):1818-1829. 6.

Bibtex

@article{9555810d303c4c00881d8bf9894d39a3,
title = "Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.",
abstract = "PURPOSE: Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone. PATIENTS AND METHODS: We analyzed 301 patients recruited from January 1986 to July 1991 (60% male; median age 15 years). Tumors of volume >100 mL and/or at central-axis sites qualified patients for {"}high risk{"} (HR, n = 241), and small extremity lesions for {"}standard risk{"} (SR, n = 52). Standard-risk patients received 12 courses of vincristine, cyclophosphamide, and doxorubicin alternating with actinomycin D (VACA); HR patients received ifosfamide instead of cyclophosphamide (VAIA). Tumor sites were pelvis (27%), other central axis (28%), femur (19%), or other extremity (26%). The initial tumor volume was or =100 mL in 67%. Local therapy was surgery (23%), surgery plus radiotherapy (49%), or radiotherapy alone (28%). Event-free survival rates were estimated by Kaplan-Meier analyses, comparisons were done by log-rank test, and risk factors were analyzed by Cox models. RESULTS: On May 1, 1999 (median time under study, 133 months), the 10-year EFS was 0.52. Event-free survival did not differ between SR-VACA (0.52) and HR-VAIA (0.51, P =.92). Tumor volume of >200 mL (EFS, 0.36 v 0.63 for smaller tumors; P =.0001) and poor histologic response (EFS, 0.38 v 0.64 for good responders; P =.0007) had negative impacts on EFS. In multivariate analyses, small tumor volumes of",
author = "M Paulussen and S Ahrens and J Dunst and W Winkelmann and Exner, {G U} and R Kotz and G Amann and B Dockhorn-Dworniczak and D Harms and S M{\"u}ller-Weihrich and K Welte and B Kornhuber and Gritta Janka-Schaub and U G{\"o}bel and J Treuner and Vo{\^u}te, {P A} and A Zoubek and H Gadner and H J{\"u}rgens",
year = "2001",
language = "Deutsch",
volume = "19",
pages = "1818--1829",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

RIS

TY - JOUR

T1 - Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.

AU - Paulussen, M

AU - Ahrens, S

AU - Dunst, J

AU - Winkelmann, W

AU - Exner, G U

AU - Kotz, R

AU - Amann, G

AU - Dockhorn-Dworniczak, B

AU - Harms, D

AU - Müller-Weihrich, S

AU - Welte, K

AU - Kornhuber, B

AU - Janka-Schaub, Gritta

AU - Göbel, U

AU - Treuner, J

AU - Voûte, P A

AU - Zoubek, A

AU - Gadner, H

AU - Jürgens, H

PY - 2001

Y1 - 2001

N2 - PURPOSE: Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone. PATIENTS AND METHODS: We analyzed 301 patients recruited from January 1986 to July 1991 (60% male; median age 15 years). Tumors of volume >100 mL and/or at central-axis sites qualified patients for "high risk" (HR, n = 241), and small extremity lesions for "standard risk" (SR, n = 52). Standard-risk patients received 12 courses of vincristine, cyclophosphamide, and doxorubicin alternating with actinomycin D (VACA); HR patients received ifosfamide instead of cyclophosphamide (VAIA). Tumor sites were pelvis (27%), other central axis (28%), femur (19%), or other extremity (26%). The initial tumor volume was or =100 mL in 67%. Local therapy was surgery (23%), surgery plus radiotherapy (49%), or radiotherapy alone (28%). Event-free survival rates were estimated by Kaplan-Meier analyses, comparisons were done by log-rank test, and risk factors were analyzed by Cox models. RESULTS: On May 1, 1999 (median time under study, 133 months), the 10-year EFS was 0.52. Event-free survival did not differ between SR-VACA (0.52) and HR-VAIA (0.51, P =.92). Tumor volume of >200 mL (EFS, 0.36 v 0.63 for smaller tumors; P =.0001) and poor histologic response (EFS, 0.38 v 0.64 for good responders; P =.0007) had negative impacts on EFS. In multivariate analyses, small tumor volumes of

AB - PURPOSE: Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone. PATIENTS AND METHODS: We analyzed 301 patients recruited from January 1986 to July 1991 (60% male; median age 15 years). Tumors of volume >100 mL and/or at central-axis sites qualified patients for "high risk" (HR, n = 241), and small extremity lesions for "standard risk" (SR, n = 52). Standard-risk patients received 12 courses of vincristine, cyclophosphamide, and doxorubicin alternating with actinomycin D (VACA); HR patients received ifosfamide instead of cyclophosphamide (VAIA). Tumor sites were pelvis (27%), other central axis (28%), femur (19%), or other extremity (26%). The initial tumor volume was or =100 mL in 67%. Local therapy was surgery (23%), surgery plus radiotherapy (49%), or radiotherapy alone (28%). Event-free survival rates were estimated by Kaplan-Meier analyses, comparisons were done by log-rank test, and risk factors were analyzed by Cox models. RESULTS: On May 1, 1999 (median time under study, 133 months), the 10-year EFS was 0.52. Event-free survival did not differ between SR-VACA (0.52) and HR-VAIA (0.51, P =.92). Tumor volume of >200 mL (EFS, 0.36 v 0.63 for smaller tumors; P =.0001) and poor histologic response (EFS, 0.38 v 0.64 for good responders; P =.0007) had negative impacts on EFS. In multivariate analyses, small tumor volumes of

M3 - SCORING: Zeitschriftenaufsatz

VL - 19

SP - 1818

EP - 1829

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 6

M1 - 6

ER -